Core B-Modeling & Experimental Therapeutics Core

核心B（建模和实验治疗核心）-摘要/总结 基因工程小鼠（GEM）模型仍然是P01几乎所有方面的核心， 对我们理解小鼠和人类胰腺癌都有重要贡献。GEM模型， 特别是那些具有可诱导致癌基因的基因，使得（i）阐明了特定遗传/途径的作用， 肿瘤生物学机制的改变，如自噬和免疫，（i）合作的解剖 基因元件如Kras* 和不同的肿瘤抑制因子如p16 ink 4a，p53和p53之间的相互作用， Smad 4，和（iii）跨肿瘤的不同细胞类型的异型相互作用的去卷积 在一些实施方案中，细胞内的TGFb可以与微环境例如癌细胞中的Kras* 和免疫细胞中的TGFb结合。在这次更新中，两个原因 促使我们建立了这个新的核心首先，每个基因组中采用的模型的极端等位基因复杂性， 项目将受益于专门的先进工程。沿着这些路线，值得注意的是，我们的模型 可能有多达十种基因变异Core B的ES-GEM系统是一个强大的平台， 将新等位基因引入到现有的具有核心PDAC相关等位基因的多等位基因ES系中。其次，几乎所有 目的是用GEM模型进行临床前实验性治疗试验。这些试验将受益于专家 由专业人员执行，其中标准化方案可以比较治疗方案 在P01。在这里，ES-GEM系统再次提供了巨大的帮助，因为它可以实现高效发电 从一轮或两轮胚泡注射中产生PDAC倾向的小鼠， 进行多组试验ES-GEM系统已被证明可以生成具有所有 生殖系模型的特征。此外，这种方法还大大减少了相关的时间和成本， 有大量的繁殖群体用于治疗实验

Core B (Modeling & Experimental Therapeutics Core) - Abstract/Summary Genetically engineered mouse (GEM) models remain central to virtually all aspects of this P01 and have contributed significantly to our understanding of both mouse and human pancreatic cancer. GEM models, particularly those with inducible oncogenes, have enabled (i) elucidation of the role of specific genetic/pathway alterations in tumor biological mechanisms such as autophagy and immunity, (i) dissection of cooperative interactions between genetic elements such Kras* and different tumor suppressors such as p16ink4a, p53 and Smad4, and (iii) deconvolution of the heterotypic interactions across different cell types of the tumor microenvironment such as Kras* in cancer cells and TGFb in immune cells. In this renewal, two reasons prompted us to establish this new Core. First, the extreme allelic complexity of the models employed in each Project will benefit from dedicated sophisticated engineering. Along these lines, it is worth noting that our models may harbor as many as ten genetic alterations. Core B’s ES-GEM system serves as a powerful platform to introduce new alleles into existing multi-allelic ES lines harboring core PDAC-relevant alleles. Second, nearly all aims propose preclinical experimental therapeutic trials with GEM models. Such trials will benefit from expert execution with professional staff where standardized protocols would enable comparison of therapeutic regimens across the P01. Here again, the ES-GEM system helps tremendously as it enables highly efficient generation of large cohorts from one or two rounds of blastocyst injection to produce PDAC-prone mice that can be enlisted into multi-arm trials. The ES-GEM system has been proven to generate experimental cohorts with all the characteristics of a germline model. In addition, this approach dramatically reduces time and cost associated with large breeding colonies for therapeutic experiments.